Biotek-snakken — September 2021
-
AstraZeneca : Enhertu Shows Robust And Durable Tumor Response Of 54.9% In Patients With Lung Cancer https://www.proinvestor.com/investornyt/706290/astrazeneca-enhertu-shows-robust-and-durable-tumor-response-of-549-in-patients-with-lung-cancer
-
Exelixis Presents Results Of Cabozantinib On Metastatic Castration-Resistant Prostate Cancer https://www.proinvestor.com/investornyt/706294/exelixis-presents-results-of-cabozantinib-on-metastatic-castration-resistant-prostate-cancer
-
Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma https://www.proinvestor.com/investornyt/706298/mercks-keytruda-shows-recurrence-free-survival-in-resected-high-risk-stage-ii-melanoma
-
Merck's Keytruda Plus Chemotherapy Reduces Risk Of Death By One-Third In Metastatic Cervical Cancer https://www.proinvestor.com/investornyt/706302/mercks-keytruda-plus-chemotherapy-reduces-risk-of-death-by-one-third-in-metastatic-cervical-cancer
-
AZN : Imfinzi Plus Chemotherapy Triples Patient Survival At 3-yrs In ES-Small Cell Lung Cancer https://www.proinvestor.com/investornyt/706313/azn-imfinzi-plus-chemotherapy-triples-patient-survival-at-3-yrs-in-es-small-cell-lung-cancer
-
Cantargia: Cantargia fremlage under ESMO konferancen "tilsydenladende" stærke data inden for lungekræft men kursudviklingen har desvære været negativ. Hvad skyldes den negative kursudvikling. Er der fremlagt konkurerende data som er stærkere. Er der en af Proinvestors mange kloge biotekskribenter som har fulgt med under ESMO og har et bud?
-
Moderna's Bigger Catalyst: Full FDA
Approval or Booster Authorization? https://www.proinvestor.com/investornyt/706328/modernas-bigger-catalyst-full-fda-approval-or-booster-authorization -
Here's Why Moderna's Stock Could Crash Before the End of 2021 https://www.proinvestor.com/investornyt/706343/heres-why-modernas-stock-could-crash-before-the-end-of-2021
-
Could Pfizer and Merck Be Big Winners
With COVID Pills? https://www.proinvestor.com/investornyt/706352/could-pfizer-and-merck-be-big-winners-with-covid-pills -
2 Biotech Stocks to Buy Right Now https://www.proinvestor.com/investornyt/706367/2-biotech-stocks-to-buy-right-now
-
Is AbbVie a Bad News Buy?
https://www.proinvestor.com/investornyt/706379/is-abbvie-a-bad-news-buy -
Will Biogen Stock Come Back Amid
Pessimism Surrounding Aduhelm Rollout?https://www.proinvestor.com/investornyt/706441/will-biogen-stock-come-back-amid-pessimism-surrounding-aduhelm-rollout -
AstraZeneca Enhertu Data Unprecedented, Should Boost Share Today, Analysts
Sayhttps://www.proinvestor.com/investornyt/706449/astrazeneca-enhertu-data-unprecedented-should-boost-share-today-analysts-say -
Ja når man nu har Zymeworks, så er det lidt ærgeligt at se Enhertu´s triumftog, når man tænker på at ZW49 burde have (haft) gode chancer med et klart bedre antistof. Måske det halter lidt på ADC/linker teknologien, men svært at vide før vi ser data sidst på året.
-
Spero - ret interessant at se GSK tage en pæn bid af Spero forleden https://newsfilter.io/a/fbfc463bc1d397541d2f1d3c2bc6e7a8. Så både Pfizer og GSK gør sig lækre. Aquilo Capital er på indkøbslisten næsten hver dag. Bliver interessant at se hvad det ender ud i med et stort antal short også...
-
Jeg er meget enig i det der blev sagt på CC, for man burde have taget det i omvendt rækkefølge - altså først kombi med godkendt checkpoint hæmmer og så kunne man eksperimenterer med en ny, så ja jeg tænker det udelukker BP med egen godkendt checkpoint inhibitor.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind